Zoledronate Versus Ibandronate Comparative Evaluation: A Randomized Phase III, Open-Label, Multicenter, Parallel Group Clinical Trial to Evaluate and Compare the Efficacy, Safety Profile and Tolerability of Oral Ibandronate Versus Intravenous Zoledronate in the Treatment of Breast Cancer Patients With Bone Metastases

Trial Profile

Zoledronate Versus Ibandronate Comparative Evaluation: A Randomized Phase III, Open-Label, Multicenter, Parallel Group Clinical Trial to Evaluate and Compare the Efficacy, Safety Profile and Tolerability of Oral Ibandronate Versus Intravenous Zoledronate in the Treatment of Breast Cancer Patients With Bone Metastases

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Ibandronic acid (Primary) ; Zoledronic acid
  • Indications Advanced breast cancer; Bone metastases
  • Focus Therapeutic Use
  • Acronyms ZICE
  • Most Recent Events

    • 08 Nov 2014 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network record.
    • 13 Mar 2013 Planned end date changed from 1 Jan 2011 to 1 Oct 2015 as reported by ClinicalTrials.gov.
    • 08 Dec 2012 Primary endpoint 'Skeletal-event-rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top